Citi: Cuts XPENG-W (09868) Target Price to HK$64, Maintains "Buy" Rating
XPENG's 2027 export target is 200,000 vehicles, accounting for only about 1.5% of expected total passenger vehicle exports, though it adopts a mid-to-high-end pricing strategy.
Citi issued a research report stating that it has cut the target price for XPENG-W (09868) by 23%, from HK$83.6 to HK$64 for Hong Kong shares, and from US$21.4 to US$16.4 for US shares, while maintaining a "Buy" rating.
The bank noted that XPeng's 2027 export target is 200,000 units, accounting for only about 1.5% of expected total passenger vehicle exports, though it adopts a mid-to-high-end pricing strategy. Management expects that by 2027, overseas net profit per vehicle could be similar to peers, namely RMB10,000 to RMB20,000; the Siasun Robot&Automation business may contribute several billion RMB in revenue and gross profit, becoming a new growth driver.
The bank expects overseas revenue to account for 30% of total revenue in the fourth quarter, with overseas gross margin at 20.8%, contributing half of gross profit; for 2027, total sales volume is expected to be 590,000 units (up 29% year-on-year), exports 205,000 units (up 105%), domestic/overseas gross margins at 9.2%/19.4% respectively; free cash flow to turn positive at RMB634 million.
The new target price applies 0.8x expected price-to-sales ratio to 2027 automotive revenue and 5x expected price-to-sales ratio to Siasun Robot&Automation revenue, both lowered, respectively reflecting risks of rising costs and possible tightening of export tax rebate policy, as well as weakening investor sentiment toward the humanoid Siasun Robot&Automation sector. The bank reiterates its investment rating, as overseas net profit per vehicle and the Siasun Robot&Automation business support the medium-term outlook.
Related Articles

HK Stock Market Move | CSTONE PHARMA-B (02616) rose over 11% in the afternoon; the company plans to initiate the global Phase III registrational clinical trial of CS2009 by the end of 2026.

No Human Intervention Needed! JPMorgan (JPM.US) Teams Up with Hyundai Card to Explore Autonomous Financial Transactions by AI Agents

HAITONG INT'L: Cuts Eastroc Beverage (09980) target price to HK$123, maintains "Outperform" rating
HK Stock Market Move | CSTONE PHARMA-B (02616) rose over 11% in the afternoon; the company plans to initiate the global Phase III registrational clinical trial of CS2009 by the end of 2026.

No Human Intervention Needed! JPMorgan (JPM.US) Teams Up with Hyundai Card to Explore Autonomous Financial Transactions by AI Agents

HAITONG INT'L: Cuts Eastroc Beverage (09980) target price to HK$123, maintains "Outperform" rating






